Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)].
Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis
may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Departments of Oncology, Department of Oncology, Hospital Grabs, Grabs
Ludwig Cancer Research Center, University of Lausanne, Lausanne
Department of Dermatology
Departments of Oncology
Private Ophthalmic Practice in Cooperation with the Skin Cancer Unit, University Hospital of Zurich, Zurich, Switzerland
Department of Dermatology, Dermatology/Allergology, Institute of Immunobiology, Kantonal Hospital St Gallen, St Gallen
Publication date: November 1, 2016